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C
linical observation and research discovery each can 
give rise to treatments that prove effective in clinical 
trials and, accordingly, are considered evidence-based. 
For example, motivational interviewing draws on, and 
addresses, clinicians’ recognition of patient ambivalence, 
and contingency management emerged from research on 
the effects of rewards on human behavior.
Whether they originate in the clinic or the research 
setting, evidence-based treatments provide clinicians with 
tools to treat patients more effectively while still treating 
each as a unique individual. Thus, motivational interview-
ing, by moving clients past ambivalence, clears the way to 
addressing other issues that are particular to the individual. 
Contingency management, similarly, can increase clinicians’ 
ability to address clients’ individual issues by motivating 
attendance in sessions and other desirable behaviors.
The future of substance abuse treatment is the develop-
ment of an increasing array of evidence-based treatments 
that clinicians will use to address patients’ varied strengths, 
needs, and circumstances. We have already begun to see 
the emergence of evidence-based treatments for patients 
with certain co-dependencies and co-occurring disorders. 
Research reviewed in this issue of Addiction Science & Clinical 
Practice suggests that interventions might be developed 
for patients in specific stages of addiction, with different 
types and degrees of cognitive impairment, or with par-
ticular genotypes.
Far from reducing the role of clinicians and the impor-
tance of the therapeutic relationship, evidence-based treat-
ments rely heavily on clinical skills and empathy. Increas-
ingly, clinicians will need to be familiar with the variety of 
available evidence-based treatments, to identify the right 
one—or combination or sequence—for each patient and 
to administer a range of assessments and interventions 
with fidelity. For substance abuse clinicians, the tools, the 
challenges, and the potential for success increase in concert.
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